Ikarian Capital, LLC Adverum Biotechnologies, Inc. Call Options Transaction History

Ikarian Capital, LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2021 May 17, 2021	SELL	$9.26 - $14.36 $2.4 Million - $3.71 Million	-258,700 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$9.84 - $14.26 $1.42 Million - $2.06 Million	-144,700 Reduced 35.87%	258,700 $2.8 Million
Q3 2020 Nov 16, 2020	BUY	$10.3 - $21.64 $460,410 - $967,308	44,700 Added 12.46%	403,400 $4.16 Million
Q2 2020 Aug 14, 2020	BUY	$8.53 - $25.64 $1.15 Million - $3.44 Million	134,300 Added 59.85%	358,700 $7.49 Million
Q1 2020 May 15, 2020	SELL	$7.98 - $16.32 $1.33 Million - $2.72 Million	-166,500 Reduced 42.59%	224,400 $10.2 Million
Q4 2019 Jan 31, 2020	BUY	$5.12 - $12.22 $2 Million - $4.78 Million	390,900 New	390,900 $4.5 Million

2.53M

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $689M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.